XTX Topco Ltd Increases Stock Position in I-Mab (NASDAQ:IMAB)

XTX Topco Ltd lifted its holdings in shares of I-Mab (NASDAQ:IMAB) by 140.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,039 shares of the company’s stock after purchasing an additional 25,163 shares during the period. XTX Topco Ltd’s holdings in I-Mab were worth $53,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Caligan Partners LP grew its holdings in shares of I-Mab by 3.7% during the third quarter. Caligan Partners LP now owns 3,499,330 shares of the company’s stock worth $4,339,000 after buying an additional 124,539 shares in the last quarter. Garden State Investment Advisory Services LLC purchased a new stake in I-Mab in the 3rd quarter worth approximately $179,000. Finally, Bank of Montreal Can acquired a new position in I-Mab in the 2nd quarter valued at $453,000. 38.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of I-Mab in a report on Friday, November 15th.

I-Mab Price Performance

IMAB opened at $0.92 on Monday. The company’s 50 day simple moving average is $1.09 and its 200 day simple moving average is $1.27. I-Mab has a 1 year low of $0.90 and a 1 year high of $2.54.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.